Skip To Main Content
Robert Mader on Muck Rack

Robert Mader

Chicago
As seen in: LinkedIn, Nature, Wiley, Wiley Online Library, Informa, Contracting Business, Contractor, HPAC Engineering, PHCP Pros, RSES Journal
Journalist focused on water and energy conservation. Editor of Plumbing Engineer magazine. #Contractors #Engineers #Plumbing #HVAC. Tweets/opinions are mine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development - Communications Biology

|
By Leopold Koenig, Robert Mader, Daniel Marbach, Inga Clausen
| Nature Verified
Abstract Hematologic adverse events are common dose-limiting toxicities in drug development. Classical animal models for preclinical safety assessment of immunotherapies are often limited due to insufficient cross-reactivity with non-human homologous proteins, immune system differences, and ethical considerations. Therefore, we evaluate a human bone marrow (BM) microphysiological system (MPS) for its ability to predict expected hematopoietic liabilities of immunotherapeutics.
Open in Who Shared Issue with article?

Application of new approach methodologies for nonclinical safety assessment of drug candidates - Nature Reviews Drug Discovery

|
By Philip Hewitt, Wenyue Hu, Robert Mader, Payal Rana, Thomas Steger-Hartmann, Mario Beilmann
| Nature Verified
Abstract The development of new approach methodologies (NAMs) and advances with in vitro testing systems have prompted revisions in regulatory guidelines and inspired dedicated in vitro/ex vivo studies for nonclinical safety assessment.
Open in Who Shared Issue with article?

Circulating microRNAs and cardiomyocyte proliferation in heart failure patients related to 10 years survival

|
By Filomain Nguemo, Robert Mader, Vilas Wagh, Zlata Kiseleva
| Wiley Online Library Verified
Introduction Modern heart failure therapy has advanced considerably from prevention to pharmacologic and device treatment, leading to reduced mortality and morbidity. Unfortunately, heart failure is progressive despite optimal treatment, leaving cardiac transplantation or left ventricle assist devices as the only real option for many patients.
Open in Who Shared Issue with article?
See all 586 articles